Tarsus director settles 201 RSUs into stock

Director David E. I. Pyott settled 201 RSUs into common shares now held in his trust and reported 9,575 indirect shares plus 605 remaining RSUs.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) director David E. I. Pyott reported the settlement and exercise of 201 Restricted Stock Units, each converting into one share of common stock, on September 15, 2026. The 201 resulting shares are held indirectly through the David E. I. Pyott Trust, which now holds 9,575 common shares. Following the transaction, Pyott also holds 605 RSUs, which vest in equal installments on September 15, 2026, December 15, 2026, March 15, 2027 and June 15, 2027, subject to continuous service as a non-employee director. The filing states that 1,383 of the trust’s shares were previously held directly and transferred to the trust with no change in Pyott’s pecuniary interest, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

201 shares exercised/converted

Exercise 2 txns

Insider PYOTT DAVID E I

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F3, F4	201	$0.00	$0.00
Exercise	Common Stock F1, F2	201	--	--

Holdings After Transaction: Restricted Stock Units — 605 contracts (Direct); Common Stock — 9,575 shares (Indirect, By the David E.I. Pyott Trust)

Footnotes (4)

1. F1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
2. F2. Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.
3. F3. Each RSU represents a contingent right to receive one share of the Company's common stock.
4. F4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Key Figures

RSUs settled: 201 units Common shares acquired by trust: 201 shares Indirect common shares after transaction: 9,575 shares +3 more

6 metrics

RSUs settled 201 units Restricted Stock Units settled into common shares on September 15, 2026

Common shares acquired by trust 201 shares Shares of Tarsus common stock received from RSU settlement and held indirectly

Indirect common shares after transaction 9,575 shares Total Tarsus common stock held by the David E. I. Pyott Trust after the reported transaction

RSUs remaining after transaction 605 units Restricted Stock Units beneficially owned following the derivative exercise/conversion

Previously directly held shares transferred to trust 1,383 shares Common shares moved from direct ownership into the trust with no change in pecuniary interest

Vesting dates for RSUs 4 installments RSUs vest on September 15, 2026; December 15, 2026; March 15, 2027; and June 15, 2027

Key Terms

Restricted Stock Units, pecuniary interest, non-employee director

3 terms

Restricted Stock Units financial

"The shares were issued pursuant to settlement of vested Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

pecuniary interest financial

"There was no change in the reporting person's pecuniary interest in the shares"

non-employee director financial

"RSUs granted in connection with the Reporting Person's service as a non-employee director"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TARS director David E. I. Pyott report on this Form 4?

He reported the settlement of 201 Restricted Stock Units into an equal number of Tarsus Pharmaceuticals common shares on September 15, 2026, with the resulting shares held indirectly through the David E. I. Pyott Trust.

How many TARS common shares does David E. I. Pyott’s trust hold after this transaction?

After the reported transaction, the David E. I. Pyott Trust holds 9,575 shares of Tarsus Pharmaceuticals common stock, including 1,383 shares that were previously held directly and transferred into the trust with no change in Pyott’s pecuniary interest.

How many TARS Restricted Stock Units does David E. I. Pyott hold after the Form 4 event?

Following the transaction, David E. I. Pyott is reported as beneficially owning 605 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Tarsus Pharmaceuticals common stock.

What is the vesting schedule for David E. I. Pyott’s TARS RSUs?

The RSUs granted in connection with his service as a non-employee director vest in equal installments on September 15, 2026, December 15, 2026, March 15, 2027, and June 15, 2027, subject to his continuous service as a non-employee director.

Were David E. I. Pyott’s TARS transactions made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked, and there is no footnote indicating that the transactions were made pursuant to a Rule 10b5-1 trading plan or other pre-arranged trading arrangement.

How did the Form 4 characterize David E. I. Pyott’s interest in the shares transferred to his trust?

It states that 1,383 shares previously owned directly were transferred to the reporting person’s trust and that there was no change in the reporting person’s pecuniary interest in those shares after the transfer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:48 PM Accepted by SEC EDGAR 09/17/2026 - 04:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PYOTT DAVID E I

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS

17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M		201	A	(1)	9,575(2)	I	By the David E.I. Pyott Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	09/15/2026		M			201	(4)	(4)	Common Stock	201	$0	605	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

2. Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.

3. Each RSU represents a contingent right to receive one share of the Company's common stock.

4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Remarks:

	/s/ Scott Sieckert, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)